Removing DayBue from the equation, over the last 3 months…
- Acadia announced 23% YoY growth in Nuplazid sales despite the fact that the drug has been on the market already for 9 years.
- Acadia has had two recent wins in patent challenges on Nuplazid, providing protection up to 2038.
- Acadia announced an acceleration in its PWS Phase 3 trial, with results now to be announced in Q4 this year.
Removing DayBue from the equation, over the last 3 months…...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.92 |
Change
0.070(0.54%) |
Mkt cap ! $1.607B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.85 | $8.049M | 616.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4175 | $12.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |